logo

Sarepta Therapeutics (SRPT)



Trade SRPT now with
  Date
  Headline
8/8/2018 4:04:01 PM Sarepta Therapeutics Q2 Loss Per Share $1.67 Vs. $1.15 Per Share Last Year
8/8/2018 4:02:52 PM Sarepta Signs Long-term Strategic Investment And License Agreements With Lacerta
7/25/2018 4:34:53 PM Sarepta Therapeutics Says Phase 1/2a DMD Micro-Dystrophin Gene Therapy Trial Placed On Clinical Hold
6/19/2018 10:29:34 AM Sarepta Presents Positive Preliminary Results From Phase 1/2a Gene Therapy Clinical Trial Assessing AAVrh74.MHCK7
6/13/2018 8:31:40 AM Sarepta Partners With Brammer Bio To Support Gene Therapy Development And Commercial Supply
6/7/2018 8:31:17 AM Sarepta Therapeutics Appoints Gilmore O’Neill As Its Chief Medical Officer
6/1/2018 7:04:05 AM Sarepta Receives Negative CHMP Opinion For EXONDYS To Treat Patients With Duchenne Muscular Dystrophy In Europe